You just read:

Keryx Biopharmaceuticals Announces Zerenex™ (ferric citrate) Meets Primary and All Key Secondary Endpoints in Phase 3 Long-Term Study as a Treatment for Hyperphosphatemia in End-Stage Renal Disease Patients on Dialysis

News provided by

Keryx Biopharmaceuticals, Inc.

28 Jan, 2013, 12:16 GMT